Editorially reviewed by Dr Fatimah Khan, registered with the Pakistan Medical and Dental Council (PMDC no. 104595-P). Editorial medical reviewer; does not prescribe or review patient assessments.
Review details
Review recorded:
Review scope: This article edition.
Editorial reviewer for Prescrivia. Editorial review does not establish participation in patient consultations.
Clinical review does not replace individual medical advice. Prescrivia is a technology intermediary; independent doctors make clinical decisions.
Legal review: Qualified review pending.
Language review: Qualified review pending.
Source and review
Source published:
Attributed source update:
Text edited:
Editorial role: Editorial team. This description does not establish an individual credential or clinical review of this edition.
Read our editorial policy and corrections. Edit dates and source descriptions do not establish qualified review.
How does semaglutide work?
Semaglutide is a GLP-1 receptor agonist. It affects appetite and blood-glucose regulation, but the same active ingredient does not make all branded products interchangeable.
The indication, formulation, eligibility and treatment plan must match the exact product. This guide uses EMA information checked on 6 October 2026; authorisation does not establish local launch, stock or access.
Wegovy, Ozempic and Rybelsus have different roles
| Product | EMA indication discussed here | Formulation distinction |
|---|---|---|
| Wegovy | Weight management alongside diet and physical activity in eligible patients | Injection pens; oral tablets for adults also appear in current EMA information |
| Ozempic | Type 2 diabetes | Injection product; not the same weight-management authorisation as Wegovy |
| Rybelsus | Type 2 diabetes | Oral tablets; not interchangeable with oral Wegovy |
For adult weight management, Wegovy's criteria include BMI at least 30, or at least 27 with a weight-related health condition. Its adolescent indication applies to injections and has separate obesity and weight criteria. Oral Wegovy is intended for adults.
Do not substitute a diabetes medicine for a weight-management product or translate injection milligrams into an oral dose yourself.
What the weight-loss studies show
The EMA Wegovy overview describes these distinct studies:
| Form and population | Follow-up | Average weight change described by EMA |
|---|---|---|
| Injection study in 1,961 adults with obesity, or overweight with a weight-related condition | 68 weeks | Around 15% loss with Wegovy versus 2% with placebo |
| Tablet study in 307 adults with obesity, or overweight with a weight-related condition | 64 weeks | Around 14% loss with Wegovy versus 2% with placebo |
These are group averages from separate trials, not a head-to-head oral-versus-injection comparison or a promised personal result. Treatment included lifestyle measures. Results in people with diabetes or in adolescents answer different questions.
Formulation and follow-up matter
The injection and tablet products have different administration and dose-escalation instructions. Follow the prescription and exact leaflet. Do not copy an older dose ladder or assume every pen has the same instructions.
Agree how tolerability, nutrition, weight, relevant blood tests and continuing need will be reviewed. Tell the clinician about other diabetes medicines and any planned procedure involving anaesthesia or deep sedation.
Safety information to know
Gastrointestinal effects include nausea, vomiting, diarrhoea and constipation. Dehydration, pancreatic or gallbladder symptoms and diabetes-related eye disease require appropriate assessment. Severe persistent abdominal pain or inability to keep fluids down needs prompt medical advice.
In June 2025, EMA concluded that NAION, an eye condition, is a very rare semaglutide adverse effect. Sudden loss of vision or rapidly worsening eyesight needs immediate medical attention; confirmed NAION requires stopping treatment under medical care.
EMA's April 2024 review did not support a causal association between GLP-1 medicines and suicidal or self-injurious thoughts. That finding does not remove the need for urgent help for thoughts of self-harm.
Current Wegovy information says not to use it during pregnancy or breastfeeding and to stop at least two months before a planned pregnancy with a clinician's treatment plan. Country-specific warnings and individual history must be checked; this guide does not import another jurisdiction's contraindications as universal EU rules.
Information and clinical decisions
This guide provides general information, not a diagnosis or personal treatment plan. Any clinical assessment and prescribing decision rests with an independent clinician. Prescrivia is a technology intermediary, not a medical provider or pharmacy; it does not prescribe, sell or dispense medicines. Assessment does not guarantee a prescription, medicine availability or a health outcome.
Further reading: treatment information.
Read about online consultations and their limits. Service information must not delay urgent local care.
Sources
- EMA: Wegovy, current medicine overview — Injection and adult oral weight-management forms, eligibility and distinct 1,961-person/68-week and 307-person/64-week trial results.
- EMA: Ozempic — Injection medicine for type 2 diabetes, distinct from Wegovy's weight-management indication.
- EMA: Rybelsus — Oral semaglutide authorised for type 2 diabetes, distinct from oral Wegovy.
- EMA: Wegovy product information — Form-specific administration, pregnancy/breastfeeding restrictions, two-month pregnancy planning interval and current safety warnings.
- EMA PRAC: NAION conclusion, June 2025 — NAION is a very rare semaglutide adverse effect; urgent assessment of sudden visual symptoms and discontinuation if confirmed.
- EMA PRAC: GLP-1 review, April 2024 — Available evidence did not support a causal association with suicidal or self-injurious thoughts; this is not an assurance against all risk.
See the current clinical, legal and language review statuses for this edition. Source checks are editorial work, not approval.